Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin

Journal of Cutaneous Pathology

Volumn 35, Issue 3, 2008, Pages 302-310

  Werner, Betina ^a,c   Bresch, Martina ^b   Brenner, Fabiane Mulinari ^a   Lima, Hermenio Cavalcante ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Immunohistochemistry Lab   (Germany)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETIN; METHOTREXATE; PSORALEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PSORIASIS; PSORIASIS VULGARIS; PUVA; SKIN BIOPSY; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

ACITRETIN; ADULT; BIOLOGICAL MARKERS; BIOPSY; CELL COUNT; FEMALE; HUMANS; KERATINOCYTES; KERATINS; KERATOLYTIC AGENTS; LANGERHANS CELLS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 38649116621     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00800.x     Document Type: Article

References (47)

1. Sobell JM, Hallas SJ. Systemic therapies for psoriasis: understanding current and newly emerging therapies. Semin Cutan Med Surg 2003 22 : 187.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004 113 : 1664.
3. Weinstein GD, McCullough JL, Ross PA. Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol 1985 85 : 579.
4. Soini Y, Kamel D, Paakko P, Lehto VP, Oikarinen A, Vahakangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994 131 : 514.
5. Kawashima K, Doi H, Ito Y, Shibata MA, Yoshinaka R, Otsuki Y. Evaluation of cell death and proliferation in psoriatic epidermis. J Dermatol Sci 2004 35 : 207.
6. Schon MP, Boehncke WH. Psoriasis. New Engl J Med 2005 352 : 1899.
7. Bovenschen HJ, Vissers WH, Seyger MM, van de Kerkhof PC. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment. Acta Derm Venereol 2005 85 : 113.
8. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon- γ, interleukin-2, and tumor necrosis factor- α, defining TC1 (cytotoxic T lymphocyte) and Th1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999 113 : 752.
9. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002 46 : 1.
10. Lebwohl M. Psoriasis. Lancet 2003 361 : 1197.
11. Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003 9 : 40.
12. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003 49 : S44.
13. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004 135 : 1.
14. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005 5 : 699.
15. Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991 24 : 598.
16. Kuijpers AL, Van Pelt JP, Bergers M, et al. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol 1998 139 : 380.
17. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol 1999 41 (Pt 2 S13.
18. Nguyen EQH, Wolverton SE. Systemic retinoids. In Wolverton, SE, ed. Comprehensive dermatologic drug therapy. Philadelphia : WB Saunders, 2001 269.
19. Geiger JM. Efficacy of acitretin in severe psoriasis. Skin Therapy Lett 2003 8 : 1.
20. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 2003 139 : 436.
21. Lee CS, Koo J. A review of acitretin, a systemic retinoid for the treatment of psoriasis. Expert Opin Pharmacother 2005 6 : 1725.
22. Elias PM. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 1986 15 (Pt 2 797.
23. Gottlieb S, Hayes E, Gilleaudeau P, Cardinale I, Gottlieb AB, Krueger JG. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996 23 : 404.
24. Gollnick HPM, Dümmler U. Retinoids. Clin Dermatol 1997 15 : 799.
25. Saurat JH. Retinoids and psoriasis: novel issues in retinoid pharmacology and implications for psoriasis treatment. J Am Acad Dermatol 1999 41 (Pt 2 S2.
26. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986 256 : 3110.
27. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992 98 : 302.
28. Elias AN, Goodman MM, Liem WH, Barr RJ. Propylthiouracil in psoriasis: results of an open trial. J Am Acad Dermatol 1993 29 : 78.
29. Vallat VP, Gilleaudeau P, Battat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994 180 : 283.
30. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995 182 : 2057.
31. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000 192 : 681.
32. Asadullah K, Friedrich M, Hanneken S, et al. Effects of systemic Interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 2001 116 : 721.
33. Gottlieb AB, Krueger JC, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002 138 : 591.
34. Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004 13 106.
35. Elias AN, Nanda VS, Barr RJ. CD1a expression in psoriatic skin following treatment with propylthiouracil, anantithyroid thioureylene. BMC Dermatol 2003 3 : 3.
36. Lago E, Carneiro S, Cuzzi T, et al. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis. J Cutan Pathol 2007 34 : 15.
37. Smit JV, de Jong EMGJ, van Hooijdonk CAEM, Otero ME, Boezeman JBM, van de Kerkhof PCM. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol 2004 51 : 257.
38. Elder JT, Astrom A, Pettersson U, et al. Retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 1992 98 (Suppl 36S.
39. Gottlieb Sl, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995 1 : 442.
40. Kopan R, Traska G, Fuchs E. Retinoids as important regulators of terminal differentiation: examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol 1987 105 : 427.
41. Steijlen PM, Reifenschweiler DO, Ramaekers FC, et al. Topical treatment of ichthyoses and Darier's disease with 13-cis-retinoic acid. A clinical and immunohistochemical study. Arch Dermatol Res 1993 285 : 221.
42. Weedon D. The psoriasiform reaction pattern. In Weedon D, ed. Skin pathology. London : Churchill Livingstone, 2002 75.
43. Ackerman AB, Böer A, Benjin B, Gottlieb GJ. Psoriasis. In Histologic diagnosis of inflammatory skin diseases. An algorithm method based on pattern analysis. New York : Ardor Scribendi, 2005. Available at http://www.derm101.com.
44. Mackee PH, Calonje E, Granter SR. Psoriasis. In Pathology of the skin with clinical correlations. Philadelphia : Elsevier-Mosby, 2005 195.
45. Mobini N, Toussaint S, Kamino H. Noninfectious erythematous, papular, and squamous diseases. In Elder DE, Johnson BL, Elenitsas R, eds. Lever's histopathology of the skin. Philadelphia : Lippincott Williams and Wilkins, 2005 183.
46. Alper M, Kavak A, Parlak AH, Demirci R, Belenli I, Yesildal N. Measurement of epidermal thickness in a patient with psoriasis by computer-supported image analysis. Braz J Med Biol Res 2004 37 : 111.
47. Patterson JA, Eisinger M, Haynes BF, Berger CL, Edelson RL. Monoclonal antibody 4F2 reactive with basal layer keratinocytes: studies in the normal and a hyperproliferative state [Abstract]. J Invest Dermatol 1984 83 : 210.